CCM
ESPR

Cinctive Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Cinctive Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,000
Closed -$2.12M – 577
2021
Q2 		$2.12M Buy
+100,000
New +$2.41M 0.1% 278

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Cinctive Capital Management's ESPR Position: Q4 2021 in Review

Cinctive Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 110,558 shares — an estimated $1.33M sold.

Cinctive Capital Management first reported a position in ESPR in Q1 2020 and held it in 7 quarters. The position peaked at $5.29M in Q3 2020. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Cinctive Capital Management reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Cinctive Capital Management sold 110,558 Esperion Therapeutics shares in Q4 2021, an estimated $1.33M.
  • Cinctive Capital Management first reported a position in Esperion Therapeutics in Q1 2020 and held it in 7 quarters.
  • Cinctive Capital Management's Esperion Therapeutics position peaked at $5.29M in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Cinctive Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.